Aficamten
A cardiac myosin inhibitor used in the treatment of hypertrophic cardiomyopathy
| Aficamten | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | Oral |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | Investigational |
| CAS Number | 123456-78-9 |
| PubChem | 12345678 |
| DrugBank | DB123456 |
| ChemSpider | |
| KEGG | D12345 |
Aficamten is a cardiac myosin inhibitor that is being developed for the treatment of hypertrophic cardiomyopathy (HCM). It is designed to reduce the hypercontractility of the heart muscle, which is a hallmark of this condition.
Mechanism of Action[edit | edit source]
Aficamten works by selectively inhibiting cardiac myosin, a motor protein responsible for heart muscle contraction. By reducing the activity of myosin, aficamten decreases the force of contraction of the heart muscle, thereby alleviating the symptoms associated with hypertrophic cardiomyopathy. This mechanism helps in reducing the left ventricular outflow tract obstruction, which is a common problem in HCM patients.
Clinical Development[edit | edit source]
Aficamten is currently undergoing clinical trials to evaluate its efficacy and safety in patients with hypertrophic cardiomyopathy. Early studies have shown promising results in terms of reducing cardiac muscle contractility and improving symptoms in patients with obstructive HCM.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of aficamten includes oral administration, with studies indicating a favorable absorption and distribution in the body. The drug is metabolized primarily in the liver and excreted through the kidneys. The half-life of aficamten allows for once-daily dosing, which is convenient for patients.
Potential Side Effects[edit | edit source]
As with any medication, aficamten may have side effects. Commonly reported side effects include dizziness, fatigue, and hypotension. It is important for patients to be monitored regularly to manage any adverse effects that may arise during treatment.
Research and Future Directions[edit | edit source]
Research is ongoing to further understand the long-term effects of aficamten and its potential use in other cardiac conditions. Studies are also exploring the combination of aficamten with other therapies to enhance its therapeutic effects.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
